Over the last 20 years, Western medical device makers have had a boom in device exports to Asia. During that time, most Asian countries’ populations have gotten wealthier, seen more government investment in healthcare, seen new, more and advanced healthcare insurance programs... Read More
In late July, Indonesia’s government announced GR 28 which is similar to the Indonesian Health Omnibus Law, but with more detailed explanations. This new regulation covers a number of topics. First, it states that the National Health Information System can use data... Read More
Japan’s medical device market is the third largest medical device market in the world, after the US and China. While it is a highly competitive market, unique products with good value propositions can be very successful there. While in the past Japan... Read More
As mentioned last year in our news brief, more and more Western drug companies are looking for new products in China. This trend has continued in 2024 as over 19 transactions valued at more than $18 billion USD were consummated in January... Read More
Earlier this year, the Indian government issued a notification upgrading its drug manufacturing requirements. This notification said that large Indian drug manufacturers had 6 months to upgrade their game, smaller Indian drug makers had 12 months. The notification said Indian drug makers... Read More
India’s National Cancer Grid (NCG) has sparked industry interest with its innovative approach to drug procurement. The pilot project, involving 23 cancer centers within the NCG network, successfully negotiated prices for 40 crucial oncology drugs, leading to significant cost savings of about... Read More
In an effort to provide better healthcare to China’s huge population, the Chinese innovative drug business is thriving. The innovation of new drugs in China is supported by both local and foreign capital as well as the Chinese government. Thus, more and more large... Read More
Ten years ago, China’s domestic firms were producing second class drug eluting stents and primarily generic drugs. However, as a result of a huge increase in Chinese venture capital, strong government support, and other financial resources, Chinese R&D in the medical space... Read More
Over the last 20 years, China’s drug business has seen tremendous growth. Western drug companies have heavily relied on China for drug products, drug substances, R&D, clinical trials, etc. However, now with increased geo-political friction between the US and China, more Western... Read More
A recent report by Bain & Company and APACMed (a MedTech trade association located in Singapore) has issued a report on Asian MedTech companies’ growing appetite for ESG initiatives. According to this report, the Asia region has doubled its ESG policies compared... Read More